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Introduction: Alzheimer’s disease (AD) and other dementias are an increasing socio-
economic burden as the population lives to reach older ages. In AD, the production of 
amyloid  (A) oligomers and downstream tau dysfunction are thought to cause neuronal 
damage, in particular a loss of synapses and synaptic plasticity, which results in cognitive 
impairment. However, epidemiological data show that vascular factors are important 
contributors to AD risk, and biomarker research has shown that the first change in AD is a 
decrease of cerebral blood flow. Because most of the vascular resistance within the brain is 
located in capillaries, this could reflect a dysfunction of contractile pericytes on capillary 
walls. Indeed, pericytes are known to regulate cerebral blood flow physiologically and to 
severely restrict blood flow after stroke. 
Rationale: We examined the role of pericytes in Alzheimer’s disease by examining cerebral 
capillaries in humans and mice developing AD, and by applying A to capillaries. We used 
freshly fixed brain biopsies from cognitively impaired living humans who were depositing A 
plaques, and carried out in vivo imaging in a knock-in mouse model of AD. We measured 
capillary diameters at positions near pericytes, in order to assess whether the capillaries 
became constricted in AD, because this would lead to a decrease of cerebral blood flow and 
hence a decrease of the glucose and oxygen supply to the brain tissue. In addition, to 
investigate one mediator already thought to be important in AD, we applied A to human brain 
slices made from normal tissue that was removed from patients undergoing neurosurgical 
glioma resection, and to rodent brain slices. A was applied in the oligomeric form, which is 
thought to contribute to cognitive decline. This allowed us to examine whether A itself might 
alter cerebral blood flow, and to use pharmacology to investigate the mechanism of any such 
effect. 
Results: Both in humans developing AD and in the mouse model of AD, capillaries were 
constricted specifically at pericyte locations, but arterioles and venules were unchanged in 
diameter. Thus, the reduction of cerebral blood flow known to occur in AD is produced by 
capillaries, rather than arterioles. The capillary constriction increased rapidly with the severity 
of A deposition, and was calculated to become sufficient in human cortex to approximately 
halve cerebral blood flow, which is comparable to the decrease of blood flow measured 
experimentally in affected parts of the AD brain. In the AD mouse cerebellum, which lacks A 
deposition at the age examined, there was no capillary constriction, supporting the idea of a 
causal link between A level and constriction of capillaries. A itself was found to constrict 
both human and rodent capillaries, by a mechanism involving the generation of reactive 
oxygen species, mainly by NADPH oxidase 4 (NOX4). The reactive oxygen species then 
triggered the release of endothelin-1, which acted on ETA receptors to evoke pericyte 
contraction, thus causing capillary constriction. The A-evoked constriction could be halted by 
blocking NOX4 and ETA receptors, and was reversed by applying the vasodilator C-type 
natriuretic peptide. 
Conclusion: These data reconcile genetic evidence for a role of A in triggering neuronal 
damage and cognitive decline in AD with the first clinically-detectable change in AD being a 
decrease of cerebral blood flow. They imply that attention should be given to vascular 
mechanisms in AD as well as to signaling pathways that act directly on neurons or glia, and 
suggest novel therapeutic approaches for treating early AD by targeting drugs to brain 
pericytes. They also raise the question of what fraction of the damage to synapses and 
neurons in AD reflects direct actions of A and downstream tau, and what fraction is a 
consequence of the decrease of energy supply that A produces by constricting capillaries. 
 
 Figure Caption 
Live human and rodent brain capillaries become constricted in Alzheimer’s disease. 
Tissue from humans and rodents (left panel) that were healthy or developing Alzheimer’s 
disease (AD) was imaged in vivo and as brain slices (middle panel), revealing that pericytes 
constrict brain capillaries early in AD via a mechanism involving ROS generation and release 
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Cerebral blood flow is reduced early in Alzheimer’s disease (AD). Because most of the 
vascular resistance within the brain is in capillaries, this could reflect dysfunction of 
contractile pericytes on capillary walls. Here we used live and rapidly-fixed biopsied 
human tissue to establish disease-relevance, and rodent experiments to define 
mechanism. We found that, in humans with cognitive decline, amyloid  (Aconstricts 
brain capillaries at pericyte locations. This was caused by A generating reactive 
oxygen species, which evoked the release of endothelin-1 (ET) that activated pericyte 
ETA receptors. Capillary, but not arteriole, constriction also occurred in vivo in a mouse 
model of AD. Thus, inhibiting the capillary constriction caused by Acould potentially 




Vascular compromise occurs early in Alzheimer’s disease (AD) (1, 2). Cerebral blood 
flow in the grey matter can be reduced by over 40% (3), and indeed reduced cerebral blood 
flow is the earliest biomarker of the development of the disease (1). Around the time that the 
amyloid hypothesis for Alzheimer’s Disease (AD) was proposed (4-6), it was reported that 
capillaries in the brains of AD patients showed an abnormal focally-constricted morphology 
(7). Although much succeeding work focused on A- and tau-evoked damage to neurons, 
increasing evidence suggests a role for vascular disturbance in the onset of AD (8, 9). 
Exogenous amyloid  canreduce cerebral blood flow (10-12), and reduced blood flow 
increases A production (13, 14).   
Investigations of the vascular effects of exogenous Ahave focused on arteries and 
arterioles (12, 15), but the majority of the vascular resistance within the brain is located in 
capillaries (16). Capillary dysfunction correlates with cognitive decline in AD (17). This 
suggests that capillaries could be the most important locus where A produced within the brain 
can act to decrease cerebral blood flow. A subset of pericytes on capillary walls is contractile 
(these are the only contractile cells on capillaries (18)) and can alter cerebral blood flow by 
adjusting their contractile tone (18-20). In a rodent model of AD there are disturbances of 
unknown origin in the control of capillary blood flow (21). We therefore investigated how 
pericytes were affected by exogenous and endogenously generated A, and in particular by 
Aoligomers, the molecular species believed to be responsible for A’s toxic effects in AD 
(22, 23). To maximise the relevance to human disease, we used living human brain slices 
derived from neurosurgically-resected brain tissue to study acute responses to Aand 
rapidly-fixed human brain biopsy tissue (from living patients with or without Adeposition) to 
assess pericyte responses to long-term accumulation of endogenous Ain AD. The effects 
seen in human tissue were also seen in vivo in a transgenic mouse model of AD and were 





Amyloid  constricts human capillaries at pericytes 
Living human brain cortex slices were obtained from tissue removed during 
neurosurgical operations to access tumours (see Materials and Methods) and either fixed for 
immunohistochemistry or imaged live to study pericyte properties. Labeling the basement 
membrane with fluorescently-tagged isolectin B4, or immunolabeling for the pericyte marker 
platelet-derived growth factor receptor  (PDGFR, revealed pericyte morphology. Pericytes 
were observed with a classical “bump-on-a-log” morphology on the straight parts of capillaries, 
or at their branch points, with processes extending along and around the capillaries (Fig. 1A, 
B). With experience, morphology alone was sufficient to identify pericytes reliably in brain 
slices (Fig. S1). The mean distance between human pericytes was 65.3±0.4 m (for 94 
pericytes imaged in tissue from 2 patients), 30% larger than in rodents (19). As for arteriole 
smooth muscle cells (Fig. 1C), the processes of 36% of pericytes labeled for  smooth muscle 
actin (Fig. 1D) and the real percentage may be significantly higher with different fixation 
techniques (24), providing a mechanistic basis for the A-evokedcontraction described below. 
In human brain slices, as previously reported for rodent capillaries (18, 19), superfused 
noradrenaline constricted and glutamate dilated the capillaries at pericyte locations (Fig. 1E, 
F). This is consistent with the circumferential processes of pericytes (which are oriented to be 
able to reduce capillary diameter) being preferentially found near pericyte somata (Fig. S2) so 
that capillary constriction by pericytes occurs predominantly near these somata (Fig. S3). 
Thus, the surgery-derived human tissue had functioning contractile pericytes (Fig. 1E-F). 
Awas oligomerised (see Materials and Methods), and silver staining of SDS-PAGE 
gels was used to assess the degree of aggregation of the Aisoforms. The predominant 
species produced (other than monomers) for A1-42 and A1-40 had a molecular weight of 2 to 
4 times that of monomers, whereas scrambled A1-42 formed mainly monomers (Fig. 1G). 
Applying soluble A(oligomeric + monomeric, 72 nM calculated from the monomeric MW) 
to human brain slices evoked a slowly developing constriction of all 4 capillaries tested, which 
reduced their diameter by ~25% after 40 mins (Fig. 1H, significantly reduced, p=0.01).  
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Because the limited availability of live human tissue precluded detailed analysis of the 
mechanism underlying the A-evoked constriction, we carried out experiments on rat cortical 
slices. As for human capillaries, A evoked a constriction of rat capillaries near pericyte 
locations that was visible using either bright field illumination or two-photon fluorescence 
imaging of isolectin B4 (Fig. 2A-C, G). Of 20 capillaries tested, 16 (80%) showed a >5% 
constriction in response to A. The time course of the mean A-evoked constriction 
(including all vessels) was similar (Fig. 2C) to that in human cortex (Fig. 1H), reaching ~15% 
after 1 hour (p=0.006). A1-40 also evoked a similar constriction (Fig. 2C, G; p=0.048) in 5 out 
of 6 capillaries tested (83%). Capillaries monitored for an hour without applying Aor those 
to whicha version of Awith a scrambled sequence was applied (prepared as for the A 
oligomers), showed no significant diameter change (Fig. 2C, G). Scrambled A1-42 mainly 
forms monomers (Fig. 1G, and see Materials and Methods), unlike A and Awhich 
may indicate that oligomer formation is obligatory for an effect on pericytes.The pericyte-
mediated constriction evoked by A showed a Michaelis-Menten dependence on A 
concentration, with an apparent EC50 (Km) of 4.7 nM (Fig. 2D).  
Reactive oxygen species and endothelin-1 generate the capillary constriction 
The A-evoked capillary constriction in rat cortical slices was blocked by the 
endothelin-1 (ET) type A receptor blocker BQ-123 (1 M, p=0.008, Fig. 2E, G), by application 
of superoxide dismutase 1 (SOD1, 150 units/ml, p=3.7x10-6, Fig. 2E, G) which scavenges 
reactive superoxide generated when A activates NADPH oxidase (and prevents hydroxyl 
radical formation by the Fenton reaction), or by inhibiting NADPH oxidase with 
diphenyleneiodonium (DPI, 10 M, p=0.032, Fig. 2F, G). In contrast, applying these agents 
alone did not affect capillary diameter (changes after 1 hour were: BQ-123, -0.7±5.2%, n=13, 
p=0.9; SOD1, 3.4±5.8%, n=9, p=0.57; DPI, -7.4±3.2%, n=5, p=0.082). The A-evoked 
capillary constriction was also abolished by BQ-123 (a 6.2±1.6% dilation was seen after 1 hour 
of A applied in BQ-123, n=5), contradicting the suggestion (25) that A1-40 does not evoke 
endothelin release. These results suggest the involvement of NADPH oxidase-mediated 
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reactive oxygen species (ROS) generation and ET release in the A-evoked capillary 
constriction. Reactive nitrogen species derived from superoxide were not involved, because 
inhibiting nitric oxide synthase (NOS) with L-NNA (100 M) had no effect (p=0.83) on the A-
evoked constriction (Fig. 2F, G; L-NNA alone had no effect: after 1 hour the diameter change 
was -0.5±7.9%, n=6, p=0.99). The fact that A evoked constrictions even in the presence of 
L-NNA also rules out the possibility that A-evoked ROS production caused constriction (26) 
by ROS binding to, and removing, vasodilatory NO. The NOX4 blocker GKT137831 (0.45 M) 
abolished the A-evoked capillary constriction (Fig. 2F, G; p=0.0011, but did not affect 
diameter when applied alone: changed by 5.7±5.6%, n=6, p=0.35 after 1 hour), whereas the 
NOX2 blocker ebselen (2 M) reduced the constriction by only 45% (n=8, p=0.027; on its own 
ebselen had no effect: diameter changed by 1.4%±3.8%, n=9, p=0.8 after 1 hour). These data 
suggest that NOX4 in pericytes or endothelial cells (27-29), rather than NOX2 in immune cells 
(28, 29), is the NADPH oxidase mainly responsible for generating the reactive oxygen species 
(ROS) that evoke capillary constriction. Data presented below in Fig. 3 suggest that the NOX4 
producing the ROS is in pericytes.  
To confirm that pericytes constrict in response to activation of ET receptors, we applied 
ET (10 nM) either alone or with a blocker of its type A (ETA) or type B (ETB) receptors. 
Endothelin-1 evoked a strong (>65%) pericyte-mediated constriction of capillaries (p=2x10-12), 
which was blocked by the ETA blocker BQ-123 (1 M, p=2.6x10-11), but not by the ETB blocker 
BQ-788 (1 M, p=0.91, Fig. 2H). ET still evoked a constriction in the presence of SOD1 
(p=1.3x10-8, Fig. 2I) implying that ET acts downstream of ROS, while generating ROS using 
H2O2 (1 mM) evoked a constriction (p=1.1x10-5) that was reduced by BQ-123 (p=0.009, Fig. 
2J), suggesting that ROS evoke constriction via ETA receptor activation. Consistent with the 
ETA receptors that generate pericyte contraction being on the pericytes themselves, we found 
that, in pericytes expressing GCaMP5G (see Materials and Methods), applying ET (10 nM) 
evoked a rise in [Ca2+]i while aCSF had no effect (Fig. 2K-L). These data establish A-
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evoked generation of ROS as being upstream of the elevated level (30, 31) (or potentiated 
effect (32)) of ET that makes pericytes constrict capillaries. 
In profound ischemia, pericyte-evoked constriction of capillaries is followed by the 
pericytes dying necrotically in rigor (caused by an excessive rise of [Ca2+]i), thus maintaining 
a decreased capillary diameter and a long-lasting decrease of blood flow (19). Pericytes also 
die after accumulating Ain AD (33). We assessed whether exposure to 1.4 M soluble A 
or 100 nM ET for 3 hours had a similar effect on pericyte health, by applying propidium iodide 
to label cells with membranes that had become non-specifically permeable, as occurs in 
ischemia (19). These treatments did not significantly increase pericyte death on this time scale 
(Fig. 2M, p=0.85 for A1-42 and 0.59 for ET). 
To assess which cell types generated ROS in response to A, in brain slices we 
employed imaging of the ROS sensor dihydroethidium, which generates fluorescence when 
oxidised dihydroethidium intercalates into DNA (see Materials and Methods). A (72 nM, 
applied for 40 mins) evoked an increase in ROS level that was suppressed by the presence 
of SOD1 (Fig. 3A, B). Previous work has suggested that ROS can be generated in response 
to A by resident microglia (34) or perivascular macrophages (35), but the cells showing the 
brightest oxidised dihydroethidium fluorescence were located on capillaries, had the 
morphology of pericytes, and labeled for NG2 but not Iba1 (Fig. 3C), implying that they are 
pericytes. The ROS signal generated in regions of interest placed over the nuclei of NG2-
expressing cells on capillaries (pericytes), or of Iba1-labeled immune cells, was quantified in 
6 image stacks (1 stack/slice) from slices not exposed to A (containing a total of 128 pericytes 
and 238 Iba1-labeled cells) and 8 stacks from slices exposed to A (containing 171 pericytes 
and 270 Iba1-labeled cells). A increased ROS production in pericytes by a factor of 7.28 
(p=0.001) and in immune (Iba1-expressing) cells by a factor of 1.76 (p=0.05). Taking into 
account the different numbers and basal ROS production of pericytes and immune cells 
revealed that Aevoked 6.4-fold more total ROS generation by pericytes than by immune cells 
(Fig. 3D). This is consistent with the data above (Fig. 2F, G) suggesting that NOX4 in pericytes 
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(27-29) is the main generator of the ROS involved in constricting capillaries early in the 
response to A.   
To confirm that both pericytes and microglia generate ROS in response to A, in brain 
slices we fluorescently imaged the level of reduced glutathione (GSH, see Materials and 
Methods), which is consumed as it scavenges ROS. A (72 nM for 40 mins) reduced the GSH 
level in pericytes by 20% and in microglia by 55% (Fig. S4, p=0.014 and p=2x10-29 
respectively). These changes cannot be converted to ROS synthesis rates because they will 
be affected by GSH regeneration rate, which may differ in microglia and in pericytes.  
Pericytes constrict capillaries in human cognitive decline patients with A deposition 
Because acute exposure to A cannot mimic the slow increase that occurs over 
decades in human AD patients, we studied rapidly-fixed brain cortical biopsy tissue from living 
patients being investigated for cognitive decline of unknown cause (for demographics, biopsy 
and tissue processing details, see Materials and Methods). Tissue sections were labeled with 
antibodies recognising residues 8-17 of A (lower panels of Fig. 4A-B) and PDGFR (upper 
panels of Fig. 4A-B). Of 13 patients, 7 turned out to have A deposition while 6 did not. 
Pericytes were readily identifiable from their PDGFR labeling. Averaging over 120-140 
adjacent fields of view (400 m square in size, randomly placed on each section as a 5x4 grid 
of squares) in tissue from the two types of patient, with the experimenter blinded to the 
occurrence of A deposition (viewing only the PDGFR image channel), we found no 
significant change in capillary density (12% larger in subjects depositing A, p=0.56, see 
Materials and Methods). However, the mean capillary diameter was reduced by 8.1% 
(p=0.0007) in the patients with A deposition (5121 diameters measured) compared to those 
without A deposition (3921 diameters measured, Fig. 4C). 
To assess whether this diameter reduction was a non-specific effect of AD, or was 
pericyte-related, we plotted the capillary diameter measurements as a function of the distance 
from the nearest PDGFR-labeled pericyte soma (see Materials and Methods). In patients 
with no detectable A deposition the capillary diameter increased at locations near pericyte 
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somata compared to at locations far from the somata (~25% larger, slope of line is significantly 
less than zero, p=3.7x10-7 for 813 data points from 6 such patients, Fig. 4D). A similar increase 
in capillary diameter near somata was previously found in rodent brain capillaries in vivo (19), 
and attributed to the presence of the soma inducing more growth of the endothelial tube. In 
contrast, in patients with A deposition, the capillary diameter was significantly reduced near 
the pericyte somata compared to locations distant from the somata (Fig. 4D; ~30% smaller, 
slope of line is significantly greater than zero, p=1.6x10-20 for 1313 data points from 7 patients), 
as expected if pericytes cause the capillary constriction by contracting their circumferential 
processes that are mainly located near their somata. The data shown in Fig. 4D are averaged 
over all measured pericytes and capillaries (and thus include pericytes on higher branch-order 
vessels that may be less contractile). For a fixed blood pressure applied at the pial vessels, 
this average constriction is predicted to reduce flow by ~50% compared to if there were no 
constriction (see Materials and Methods), which is similar to the 42% decrease observed in 
the grey matter in patients with AD (3).  
The pericyte soma-specific location of the constriction (Fig. 4D) is consistent with the 
distribution of circumferential processes relative to pericyte somata (Fig. S2) and the fact that 
exogenous vasoconstrictors constrict capillaries specifically at pericyte locations (Fig. S3; 
(18)). These data, and the fact that no other cells on capillaries show contractile activity (18), 
imply that it is pericytes that constrict capillaries in human patients depositing A.  
Pericyte constriction of human capillaries increases with A load 
The subjects were classified by neuropathologists assessing the A-labeled biopsies 
as having “no A deposition”, “moderate A deposition” or “severe A deposition” in the 
parenchyma (as diffuse deposits and/or as plaques with central amyloid cores, Fig. 4E). The 
mean slope for individual patients, from graphs like those in Fig. 4D, for 6 patients with no A 
deposition, 3 patients with moderate deposition and 4 patients with severe A deposition, 
showed a progressive change from negative (implying a larger capillary diameter at the soma) 
to positive (implying a smaller diameter at the soma) as the severity of the Adeposition 
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increased (Fig. 4F, p=0.003 compared with a relationship with zero slope). This further 
supports the idea that Ais the cause of the capillary constriction.  
To quantify A levels more rigorously, we measured light absorption by the peroxidase 
product generated by the A antibody, in the region where the vessel diameters were 
measured in each biopsy (see Materials and Methods; although this measure of A may 
largely reflect the presence of plaques, it is likely that the soluble A concentration correlates 
with plaque load). Plotting the slopes of graphs like those in Fig. 4D, for each biopsy, as a 
function of the amount of A deposition, again showed a monotonic progression from a 
negative slope to a positive slope as A deposition increased, but with the change of slope 
occurring more strongly at low levels of A deposition (Fig. 4G). Similarly, plotting the value of 
the capillary diameter at the pericyte soma for each biopsy (extrapolated from a straight line 
fit as in Fig. 4D) as a function of A deposition showed that the diameter was reduced strongly 
by low levels of A, with smaller increments of constriction as deposition increased (Fig. 4H). 
This presumably reflects the dose-response curve of Fig. 2D (although it could also reflect 
increased A production when blood flow is less). 
Pericytes constrict capillaries in vivo in AD mice 
To confirm that pericytes constrict capillaries in vivo in AD (i.e. that the constriction 
seen in human biopsy tissue was not an artefact of fixing the tissue), and to provide a possible 
framework for future testing of drugs to prevent this constriction, we used in vivo two-photon 
imaging of layers I-IV of the somatosensory cortex (Fig. 5A, B) in a mouse model of AD, in 
which APP with a humanised A region with 3 AD-related mutations (AppNL-G-F) is knocked in 
(see Materials and Methods). Comparing 4 homozygous AD mice and 3 wild-type (WT) mice 
(age range P119-P143, when the AD mice already show plaques: Fig. 5C) revealed that, as 
in human subjects with and without A deposition, in AD mice the mean capillary diameter 
was less (Fig. 5D, p=1.7x10-9), and the diameter at pericyte somata was more strongly 
reduced (Fig. 5E, p=1.6x10-17). A plot of capillary diameter as a function of distance from 
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pericyte somata showed a dilation at the soma in WT mice, but a constriction in the AD mice 
(Fig. 5F), relative to the diameter midway between somata (cf. Fig. 4D).  
To check whether capillary constriction was present throughout the brain of AD mice, 
or occurred only where A levels rise, we imaged capillaries in vivo in the cerebellum: an area 
that is relatively spared of amyloid plaque pathology in humans, and that had no plaques in 
our AD mice at P120-140 (Fig. S5) suggesting lower levels of A oligomers. In cerebellum, 
both WT and AD mice (n=3 each) showed a larger capillary diameter near pericyte somata 
(Fig. 5G, p=0.002), with no evidence for a constriction in the AD mice. Thus, capillary 
constriction is associated with amyloid  production. 
Exogenous Ahas been reported to constrict isolated penetrating arterioles (12) but, 
at the endogenous level of Aproduced in the AD mice, arterioles (and venules) were not 
constricted (Fig. 5H). This may reflect a different response of pericytes and of arteriolar smooth 
muscle cells to the endothelin-1 released by A (Fig. S6). The lack of arteriole constriction that 
we observed in the AD mice (Fig. 5H) suggests that capillary constriction is the cause of the 
decrease in cerebral blood flow that occurs in early AD (1). 
Hypoxia is increased in the AD cortex  
 Our measured capillary constrictions are predicted to decrease cerebral blood flow 
significantly in AD (see above and Materials and Methods), as has been observed in human 
patients and AD mice (1, 17, 21). Consistent with this, hypoxic tissue labeling by pimonidazole 
(hypoxyprobe) was increased significantly in vivo in the AD mice (Fig. S7). 
Reversal of A-evoked capillary constriction 
Prevention or reversal of A-evoked capillary constriction and tissue hypoxia could be 
a promising therapy in early AD. In brain slices, we investigated two strategies to achieve this 
(Fig. S8), assuming it were possible to target drugs specifically to central nervous system 
(CNS) capillaries. The first strategy involved combined block of the ROS generator NOX4 (with 
GKT137831, 0.45M, Fig. 2F) and of the downstream constricting ETA receptor (with BQ-123, 
1 M, Fig 2E). This prevented further constriction evoked by A (p=0.027), but did not reverse 
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the capillary diameter to its baseline value on a 1 hour time scale (Fig. 6A). The second 
strategy employed C-type natriuretic peptide (CNP), which can reverse ET-mediated effects 
(36) by blocking Ca2+ release from internal stores and activating myosin light chain 
phosphatase (Fig. S8). Remarkably, CNP (100 nM) reversed the A-evoked capillary 
constriction (p=0.029, Fig. 6A). 
 
Discussion 
Genetic evidence strongly implicates A in triggering neuronal damage and cognitive 
decline in Alzheimer’s disease, yet the first change in AD is a decrease of cerebral blood flow 
(1). Our data make five contributions to understanding the vascular effects of A and their role 
in Alzheimer’s disease: (1) A constricts human and rodent capillaries by acting on pericytes; 
(2) the mechanism of this constriction involves ROS generation and ET release; (3) in rapidly 
fixed biopsies from living human patients with A deposition and cognitive decline, cortical 
capillaries are constricted by 30% at pericyte locations which is sufficient to produce a major 
reduction of cerebral blood flow; (4) in vivo, in a rodent model of AD, capillaries are constricted 
by pericytes; and (5) it is in principle possible to reverse the A-evoked capillary constriction. 
Together, these data imply that the reduction in cerebral blood flow which occurs early in AD 
results from A-evoked pericyte-mediated constriction of the cerebral capillary bed (Fig. 6B). 
At low nanomolar concentrations, exogenous soluble Aoligomers evoke a 
constriction of human and rat cortical capillaries, which is mediated by pericytes. Capillaries 
are the site in the cortical vasculature where most of the resistance to flow is located (16), and 
so may be the major site where A produced within the brain can produce vessel diameter 
changes that reduce cerebral blood flow. In rodents the capillary constriction was the result of 
A evoking the generation in pericytes and microglia of reactive oxygen species, which evoked 
a release of endothelin-1 that acted via ETA receptors to make pericytes constrict the 
capillaries. We assume that the ETA receptors involved are located on the pericytes 
themselves, since ET raised the [Ca2+]i in pericytes, but we cannot rule out the possibility that 
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they are on a different cell type. The EC50 for the action of A1-42, 4.7 nM, is comparable to the 
concentration of soluble Afound in the human AD brain (6 nM, from Table 1 of ref. (37); it is 
important to note that this brain concentration is higher than the level found in the CSF, which 
falls during the development of AD as plaques are formed). Thus, wherever A is produced, 
or can diffuse, in the AD brain, we would expect all contractile pericytes in that region to 
constrict capillaries. Indeed, our live human biopsy and in vivo mouse imaging data show that 
the endogenous level of A reached in AD is sufficient to constrict capillaries. However some 
ageing humans accumulate A and yet do not develop AD - future work could examine 
whether, in such people, compensation for the vasoconstricting effects of A develops, such 
as an upregulation of vasodilatory mechanisms.  
Throughout this work pericytes were identified by their morphology (spatially isolated 
cells located outside capillaries) as confirmed by isolectin B4 labelling, or by antibody labelling 
for their characteristic marker PDGFR, or by expression of dsRed under the NG2 promoter. 
Although arterioles (recognised as being surrounded by rings of abutting smooth muscle cells) 
have also been reported to be constricted by exogenous A (12), in AD mice we found no 
constriction of arterioles. This may be because, at the endothelin-1 level reached during AD 
pathology, endothelin constricts capillaries but has opposing dilating and constricting effects 
on arterioles, mediated by different types of ET receptor, which may approximately cancel out. 
Further work assessing the level of A reached in the AD mice, and the relative affinity of the 
constricting ETA and dilating ETB receptors, will be needed to test this idea. 
Three results demonstrate that the effects of A on pericytes that we have 
demonstrated are pathologically relevant in AD. First, analysing the diameter of capillaries in 
biopsies from living human patients with cognitive decline, who either had or lacked 
Adeposition showed that Alzheimer’s pathology leads to capillary constriction specifically at 
pericytes. Second, the magnitude of the capillary constriction in human dementia patients 
increased with the severity of A deposition and is predicted to produce a decrease of cerebral 
blood flow (~50%) similar to the 42% seen in AD patients (3). Capillary constriction by 
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pericytes may explain why some capillaries become occluded by neutrophils in AD (37) but 
neutrophil-block of 2% of capillaries, as observed, was predicted to reduce blood flow by only 
5% (38). Finally, in a mouse model of AD, in vivo imaging showed that cerebral capillaries 
were constricted at pericyte locations, while arterioles and venules were unaffected.  
Both the reduction of basal blood flow produced by A, and a reduction in the blood 
flow increase normally produced by neuronal activity (39), which may also reflect the 
constricting action of A on pericytes, will decrease the energy supply to the brain. This in turn 
increases Aproduction by upregulating -amyloid converting enzyme (-secretase 1, 
BACE1) (13, 14). Consequently, the pericyte-mediated capillary constriction evoked by 
Amay act as an amplifying mechanism in a positive feedback loop (Fig. 6B), increasing the 
levels of Aand downstream hyperphosphorylated tau which ultimately lead to the loss of 
synapses and neurons. 
These data suggest several potential therapeutic approaches for early AD, based on 
the mechanisms generating pericyte constriction. A-evoked generation of reactive oxygen 
species by NOX4 in pericytes might be targeted. Indeed, overexpression of SOD1 in APP-
overexpressing mice abolishes the lethal effects of the APP overexpression (40, 26). Another 
approach might be to try to reduce endothelin-1 release (presumably from brain cells 
expressing endothelin-1 strongly, i.e. endothelial cells, microglia or pericytes (28, 29)) or to 
block the effects of endothelin-1 on its ETA receptors on CNS pericytes. In a proof-of-concept 
experiment, a combination of a NOX4 blocker and an ETA blocker prevented further A-
evoked constriction (and could conceivably reverse the existing constriction given sufficient 
time) while CNP, which acts via two separate pathways downstream of ET (Fig. S8), was able 
to reverse the constriction in the maintained presence of A. These therapeutic approaches 
could be tested by targeting drugs to CNS pericytes in the mouse model of AD which also 
shows the pericyte-mediated constriction of capillaries. Finally, our scheme (Fig. 6B) prompts 
the question of what fraction of the damage to synapses and neurons in AD reflects direct 
15 
 
actions of A and downstream tau, and what fraction is a consequence of the decrease of 





Materials and Methods 
Human brain slices 
The work on fresh living human brain tissue received ethical approval from the National 
Health Service (REC number 15/NW/0568) and all patients gave informed consent. During 
neurosurgical operations for tumour treatment, apparently normal cortical tissue that was 
removed (to gain access to the tumour), which would otherwise have been discarded, was 
placed in ice cold brain slicing solution containing (mM) 93 N-methyl-D-glucamine (NMDG) 
chloride, 2.5 KCl, 30 NaHCO3, 10 MgCl2, 1.2 NaH2PO4, 25 glucose, 0.5 CaCl2, 20 HEPES, 5 
Na ascorbate, 3 Na pyruvate, 1 kynurenic acid (to block glutamate receptors, to prevent 
excitotoxic damage to neurons during the slicing: the experimental solution lacked kynurenic 
acid, as described below). This solution was oxygenated by gassing with 95% O2/5% CO2, 
and transported in less than 15 mins to the laboratory. Tissue was cut into 200 m sections 
and the slices were incubated at 34oC in the same solution for 10 mins, and then incubated at 
room temperature until used in experiments in a similar solution (41) with the NMDG-Cl, MgCl2 
and CaCl2 replaced by (mM) 92 NaCl, 1 MgCl2 and 2 CaCl2. Each patient’s tissue typically 
generated ~2 brain slices. When sufficient tissue was present, histological examination of the 
slices using haematoxylin and eosin by neuropathologists was used to assess tumour 
infiltration into the nominally normal tissue. This revealed that while some slices showed no 
infiltration by the tumour, others did. A was only applied to slices that showed no tumour 
infiltration. Pericyte responses to noradrenaline and glutamate as documented in Fig. 1 were 
observed whether or not there was tumour infiltration.  
Rodent brain slices 
 Experiments used P21 Sprague-Dawley rats or transgenic mice as described below of 
either sex. All animal procedures were carried out in accordance with EU and UK regulations. 






 Human and rodent brain slices were superfused at 3-4 ml/min with artificial 
cerebrospinal fluid (aCSF) solution containing (mM) 124 NaCl, 2.5 KCl, 26 NaHCO3, 1 MgCl2, 
1 NaH2PO4, 10 glucose, 2 CaCl2, 1 Na-ascorbate. This solution was gassed with 20% O2/75% 
N2/5% CO2, which produces a physiological level of oxygen in the slice near the capillaries 
being imaged (19). Mechanism-blocking drugs were superfused for 5-15 mins before applying 
A or ET. 
Imaging capillaries in brain slices 
 Healthy capillaries (<10 m in diameter, mean diameter 5.61±0.03 m (n=299) in rat, 
and 5.08±0.33 m (n=12) in human, with no rings of arteriolar smooth muscle around them) 
were selected as previously described (41), and regions of them were imaged which were in 
focus in a single image plane over at least 30 m along the length of a capillary and which 
exhibited a candidate pericyte with a bump-on-a-log morphology (Figs. 1E, 2A). A CCD 
camera was used to capture images 100 m square during superfusion of drugs. Capillary 
diameter was measured from the resulting movies, by an analyst blinded to the time and 
identity of drug application, by placing a line across the lumen on magnified images using 
Metamorph software. In some experiments pericytes were identified prior to imaging by 
incubating slices for 30 min in 10 g/ml isolectin B4 conjugated to Alexa 488 or 568 
(ThermoFisher I21411 or 121412), which binds to -D-galactose residues in the basement 
membrane generated by pericytes and endothelial cells, and outlines pericytes (41). This also 
allowed two-photon imaging (using a Zeiss LSM710 microscope, excitation wavelength 800 
nm) of the endothelial tube and the pericytes on it (Fig. 2B).  
Oligomerising A and assessing the form and concentration of A applied 
 The method employed to generate oligomeric Aβ preparations was modified from that 
previously described (42). Synthetic Aβ1-42 (Bachem H-1368.1000), Aβ1-40 (Bachem H-
1194.1000) and scrambled Aβ1-42 (Bachem H-7406.1000) were suspended in 1,1,1,3,3,3 
hexafluoro-2-propanol (HFIP; 52527, Sigma) at 1 mM, vortexed to obtain a homogenous 
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solution, and aliquoted to microcentrifuge tubes. The HFIP was removed by overnight 
evaporation and the A was completely lyophilised via a Speed-Vac. The Aβ peptide films 
were stored desiccated at -80oC until further processed (within 2 weeks). The peptide films 
were then resuspended at a nominal 5 mM in DMSO, bath-sonicated for 10 min and vortexed 
for 30 sec. To form Aβ oligomers, this solution was diluted to a nominal 100 μM with 
phosphate-buffered saline, vortexed for 15-30 sec and incubated at 4oC for 24 h. Immediately 
before use, the oligomeric preparations were centrifuged at 14,000 g for 10 min at 4oC (to 
remove any fibrils that might be present) and the supernatants were further diluted to the final 
experimental concentrations (quantified below) with extracellular solution.  
Quantification of A peptide concentration was performed using a Pierce BCA protein 
assay kit (ThermoFisher 23227), calibrated against a known concentration of bovine serum 
albumin, taking into account the different chromophoric development of albumin and A 
peptides by multiplying by a factor of 1.51 (43, 44). This showed that the amount of the 
molecule remaining as soluble monomers and oligomers (i.e. not undissolved or removed as 
fibrils) was 28.7±2.9% (n=4) of the nominal concentration added for A1-42, 39.9±1.5% (n=4) 
for A1-40, and 43.6±2.3% (n=3) for scrambled A1-42. Concentrations stated in the text have 
been corrected for these factors, and are given based on the monomeric molecular weight. It 
was not possible to make pure monomeric preparations of A1-42 or A1-40. 
 The A oligomeric preparations were analysed via SDS-PAGE using 10-20% tris-
glycine gels (EC61352BOX, Invitrogen). Samples of 50 μg Aβ peptides were added to tris-
glycine SDS Sample Buffer (LC2676, Invitrogen). Equal volumes of each sample (10 μl) were 
loaded onto gels along with SeeBluePlus2 (Invitrogen) pre-stained molecular weight markers, 
and electrophoretically separated at 100 V. Gels were stained for total protein using a 
SilverXpress Silver Staining kit (LC6100, Invitrogen) according to the manufacturer’s protocol. 
Aβ1-42 and Aβ1-40 formed monomers and oligomers, while scrambled Aβ1-42 formed mainly 
monomers (Fig. 1G). Using densitometry we estimated that for Fig. 1G the percentages of 
Aβ1-42, Aβ1-40 and scrambled Aβ1-42 present as monomers (defined as molecular weight 2.5-6.5 
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kD) were 48%, 39% and 89% respectively; the percentages as dimers (MW 6.5-11.5 kD) were 
11%, 46% and 11%; the percentages as trimers (MW 11.5-15.5 kD) were 22%, 6% and 0%; 
and the percentages as tetramers (MW 15.5-20.5 kD) were 19%, 4% and 0%. Thus, the 
measured EC50 of 4.7 nM for the effect of A1-42 on constriction in Fig. 1D, which was 
calculated based on the monomeric molecular weight, would become approximately 4.7x0.19 
= 0.9 nM if only the tetramer was active. 
Immunohistochemistry of non-biopsy tissue 
Human and rat brain slices were fixed in 4% paraformaldehyde (PFA) for 1 hour, 
washed 3 times in phosphate-buffered saline (PBS), then blocked in 10% goat serum/0.5% 
Triton X100 in PBS. Primary antibodies for PDGFR (Santa Cruz, sc432, 1:200) or α-SMA 
(Santa Cruz, CGA7, 1:200) or A (IBL, 82E1, 1:500) were applied overnight, followed (after 
washing in PBS) by application overnight of Alexa Fluor 647 or 633 conjugated secondary 
antibodies (ThermoFisher, A-21245, A-21070, A-21050, 2 g/ml). Slices were then washed 
once in PBS containing DAPI nuclear stain (1:50,000) for 10 mins and then washed again in 
PBS. After mounting, slices were imaged on a Zeiss LSM700 confocal microscope. 
Imaging pericyte [Ca2+]i 
Experiments were carried out on acute cortical brain slices from P44-P88 mice, of 
either sex, generated by crossing tamoxifen-inducible NG2-CreERT2 mice (45) with floxed 
GCaMP5G-IRES-tdTomato mice (JAX 024477). Co-expression of the genetically encoded 
Ca2+ indicator GCaMP5G and the morphological marker tdTomato (driven by the CAG 
promoter after Cre-mediated recombination) was induced by oral gavage of tamoxifen (1 
mg/10 g bodyweight) for four consecutive days (starting from P23). Brain slices (300 μm thick) 
were prepared from 21 days after the first tamoxifen administration, as described above for 
human and rat brain slices. Cortical capillary pericytes, identified in the tdTomato channel from 
their bump-on-a-log somatic morphology and processes wrapped around capillaries, were 
imaged using a two-photon microscope (Zeiss LSM 710 or 780) with the two-photon laser 
(Ti:sapphire Mai Tai DeepSee, Spectra Physics) tuned to 940 nm. Images were acquired with 
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a 20x/1.0 NA water immersion objective (W Plan-Apochromat, Zeiss). Laser power was 5-20 
mW in the focal plane. Emitted fluorescence was spectrally divided by a 555 nm dichroic 
mirror, and collected by GaAsP detectors. Two-photon image stacks (50-200 m x 50-200 m 
x 20-40 m, 150-300 nm pixel size, 2 μm z-step size, 1.58-2.55 μs pixel dwell time) were 
acquired every 30 seconds, and processed using FIJI (ImageJ). Image-stacks were first 
maximum intensity projected in the z-dimension, and both channels were co-registered to 
correct for movement artefacts using the FIJI plugin Multistackreg. Percentage changes in the 
GCaMP5G fluorescence of regions of interest (ROIs) drawn around pericyte somata were 
calculated. Oligodendrocyte precursor cells (OPCs), identified based on a star-like 
morphology and weaker baseline fluorescence, and arteriolar smooth muscle cells, were 
excluded from the analysis.  
Assessing pericyte death 
This was carried out as previously described (19). Briefly, brain slices (250 m thick) 
were incubated at 36±1°C in a multi-well plate, with 95% O2/5% CO2 blown gently at the 
surface, in aCSF, or aCSF with oligomerised A1-42 or ET added. All extracellular solutions 
contained isolectin B4 (41) to label the basement membrane (ThermoFisher I21411, 10 g/ml), 
and hence to label pericytes which are enveloped by this (Fig. 1B), and 7.5 M propidium 
iodide to label cells with membranes that had become non-specifically permeable (19). After 
3 hours incubation, slices were fixed in 4% PFA for 2 hours, washed 3 times with PBS for 15 
mins each, mounted in DAKO medium and imaged on a confocal microscope. To avoid 
counting cells killed by the slicing procedure, quantification of the percentage of pericytes that 
were dead excluded cells within 20 m of the slice surface. 
Imaging ROS production 
Cellular production of reactive oxygen species (ROS) in brain slices was visualised 
through the O2.-specific oxidation of dihydroethidium to ethidium, which binds to the DNA and 
RNA of O2.-producing cells (46). Rat cortical slices (250 m thick) were incubated in aCSF or 
in aCSF containing A (72 nM) or A + SOD1 (150 units/ml) at 34ºC. Dihydroethidium 
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(DHE, 8 M, Cayman, 104821) was added to all solutions immediately before use to avoid 
auto-oxidation of the dye. No preincubation with DHE was used, to limit the intracellular 
accumulation of oxidised product. After 40 min, the slices were quickly rinsed in PBS, mounted 
and immediately imaged using a confocal microscope. A single image stack was acquired at 
the middle of each slice and for Fig. 3B the fluorescence intensity of the maximum intensity 
projections was measured using ImageJ. For establishing the identity of ROS-producing cells, 
slices were fixed in 4% PFA for 20 min and immunostained for NG2 (Millipore AB5320, 1:200) 
and Iba1 (Synaptic Systems 234006, 1:200). Alexa 488-isolectin B4 (ThermoFisher I21411, 
10 g/ml) was added with the secondary antibodies to also label blood vessels. In maximum 
intensity projections of z-stacks, ROIs were then drawn around the nuclei of pericytes (NG2-
expressing cells on capillaries) and Iba1-expressing immune cells (microglia and perivascular 
macrophages) and the DHE signal within each ROI was measured in ImageJ. For each z-
stack, a mean intensity per pericyte or Iba-1-labeled cell, and the total intensity per population 
of pericytes or Iba1-labeled cells, were calculated, and analysis was performed using the z-
stack as the statistical unit. 
For glutathione imaging, rat brain slices were incubated with A and fixed as described 
above, then incubated with 10 mM N-ethylmaleimide (NEM) for 4 h at 4ºC and washed 
thoroughly with PBS. The sections were additionally immunolabeled with a GSH-NEM 
antibody (Millipore MAB3194, 1:500) which is specific to this adduct, allowing quantification of 
reduced glutathione after reaction with NEM (47). Following confocal imaging, ROIs were 
drawn around the soma of IB4-labeled pericytes and Iba1-expressing immune cells as above 
and the total fluorescence signal for GSH-NEM was quantified for each cell and averaged over 
cells. 
Human biopsy data 
 Diagnostic brain biopsies, comprising cortex and subcortical white matter, were 
performed as part of routine clinical investigation at the National Hospital for Neurology and 
Neurosurgery, Queen Square, London, to exclude treatable causes of neurological symptoms 
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that patients showing cognitive decline had presented with. All patients gave informed consent 
for the biopsy. The use of human tissue samples was licensed by the National Research 
Ethical Service, UK (University College London Hospitals NRES license for using human 
tissue samples, project ref 08/0077). The storage of human tissue was licensed by the Human 
Tissue Authority, UK (License #12054).  
Biopsies (volume typically 1 cm3) were all from the right frontal lobe. The biopsies were 
fixed in 10% buffered formalin less than 30 mins after the resection, for a minimum of 12 hours. 
The formalin-fixed tissue was dehydrated through graded alcohols and embedded in paraffin 
wax, from which 4 µm thick sections were cut for routine haematoxylin and eosin staining and 
a panel of immunohistochemical stains. As part of the diagnostic work up, the sections were 
immunostained for Aβ with immunoperoxidase-labeled antibody 6F3D (DAKO, 1:50), and for 
this study in addition with antibody against PDGFR (RD systems, MAB1263, 1:20) to label 
pericytes. This was performed on a Roche Ventana Discovery automated staining platform 
following the manufacturer’s guidelines, using biotinylated secondary antibodies and 
streptavidin-conjugated horseradish peroxidase and diaminobenzidine as the chromogen. The 
extent of parenchymal Aβ deposition was assessed semi-quantitatively as absent, moderate 
or severe by a neuropathologist. In addition, to objectively quantify A deposition, the images 
of the immunoperoxidase label for A were imported into ImageJ, and split into red, green and 
blue channels. Then, the light intensity in the blue channel (which gave best distinction of the 
immunoperoxidase label from the background tissue haematoxylin labeling) was measured in 
the region of the biopsy where diameters were measured, normalised by the intensity in a 
region of the section showing no visible A label and converted to a percentage of light 
absorbed by the A. Normalising by the intensity in a (tissue-free) region without any tissue 
absorption gave values that were 5.8±0.5% larger, which did not materially change the form 
of the graphs. Although this measure of A may largely reflect the presence of plaques, it is 
likely that the soluble A concentration correlates with plaque load (48). 
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The mean age of patients without Aβ deposition was 50.5±5.5 (n=6, 4 women and 2 
men), and of those with Aβ deposition was 62.1±4.2 (n=7, 4 women and 3 men, not 
significantly different, p=0.11). Regressing mean capillary diameter against age from all 
patients, or from the patients lacking A deposition, showed that there was no significant 
dependence on age (p=0.5 and p=0.82 respectively). 
 Images were analysed to assess capillary diameter with the experimenter blinded to 
the level of A deposits (i.e. viewing only the PDGFR channel: the condition of the tissue was 
sometimes worse for patients with Adeposition, but it was not possible to unambiguously 
decide whether the patient had A deposition without viewing the A channel). A standard 5x4 
grid of 20 squares (each with sides 400 m long) was superimposed on each image, and all 
capillaries with clearly demarcated endothelial walls visible in each square had their diameter 
measured. The image squares were treated as the experimental unit for statistical analysis. 
Analysis of the diameter as a function of distance from the nearest visible pericyte employed 
a subset of all the measured diameters, because often no pericyte was visible on some short 
capillary segments. The total number of measurable capillary segments (within the 5x4 grid) 
per subject was not significantly different (p=0.56) between subjects depositing A (732±96) 
and subjects not depositing A (654±88), suggesting no detectably greater loss of capillaries in 
the subjects depositing A 
Experiments in vivo on AD mice  
AD mice, in which APP with a humanised A region containing 3 AD-related mutations 
(AppNL-G-F) is knocked in (49), to avoid artefacts associated with over-expressing APP, were 
crossed with NG2-DsRed mice in which pericytes express DsRed (19). Mice aged ~4 months 
(P119-P143, not significantly different for WT and AD, p=0.13) were anesthetised using 
urethane (1.55 g/kg given in two doses 15 minutes apart). Adequate anesthesia was ensured 
by confirming the absence of a withdrawal response to a paw pinch. Body temperature was 
maintained at 36.8+0.3°C and eyes were protected from drying by applying polyacrylic acid 
eye drops (Dr. Winzer Pharma). The animal was secured in a stereotaxic frame and 
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lidocaine/prilocaine (AstraZeneca) was applied topically prior to exposing the skull. A custom 
built headplate was then attached to the skull using superglue to create a sealed well filled 
with HEPES-buffered aCSF (in mM: 140 NaCl, 10 HEPES, 2.5 KCl, 1 NaH2PO4, 10 glucose, 
2 CaCl2, 1 MgCl2) during imaging. A craniotomy of approximately 3 mm diameter was 
performed over the right primary somatosensory cortex, immediately caudal to the coronal 
suture and approximately 2-6 mm laterally from the midline, or over the right cerebellar 
hemisphere for imaging cerebellar vessels. The dura was left intact, to reduce perturbation of 
the brain. During imaging, the headplate was secured under the objective on a custom built 
stage. 
 Cortical or cerebellar vessel diameter was recorded using two-photon microscopy of 
the intraluminal dyes Cascade Blue dextran (MW 10 kDa, Invitrogen, D1976, 1.25 mg in 100 
µl saline given i.v.) or albumin–fluorescein isothiocyanate conjugate (FITC-albumin, Sigma, 
A9771, 1 mg in 100 µl saline given retro-orbitally). Two-photon excitation was carried out using 
a Newport-Spectraphysics Ti:Sapphire MaiTai laser pulsing at 80 MHz, and a Zeiss LSM710 
microscope with a 20x water immersion objective (NA 1.0). Fluorescence was evoked using 
a wavelength of 920 nm for DsRed, 820 nm for FITC-albumin and 800 nm for Cascade-Blue. 
The mean laser power under the objective did not exceed 35 mW. Penetrating arterioles >10 
µm in size were identified by the typical ring shape of vascular smooth muscle cells expressing 
DsRed in NG2-DsRed (wild-type or APPNL-G-F) mice. Image stacks were taken in 2 m depth 
increments across layers I-IV of the cortex (up to 400 μm deep from the cortical surface). To 
measure vessel diameter, a line was drawn in ImageJ across the vessel perpendicular to its 
axis and the width of the intraluminal dye fluorescence was measured, either manually or 
using an automated routine fitting a Gaussian function to the fluorescence profile in ImageJ 
and calculating the full width at quarter-maximum of the peak fluorescence intensity (which 





Assessing hypoxia in vivo with pimonidazole 
Hypoxia was assessed in vivo using the Hypoxyprobe-Plus (HP2-100, Hypoxyprobe 
Inc.) kit following the manufacturer’s instructions. Following anesthesia induction with 3% 
isoflurane in air, animals were switched to 1.5% isoflurane in air and 60 mg/kg pimonidazole 
HCl was injected intraperitoneally. Four hours after pimonidazole injection, animals were 
transferred to 1.55g/kg urethane anesthesia and sacrificed by perfusion fixation. Brains were 
extracted and kept in paraformaldehyde for 24 hours prior to sectioning for immuno-
histochemistry using the FITC-conjugated antibody provided in the kit which recognises 
conjugates of pimonidazole with protein SH groups in hypoxic cells.  
Statistics 
Data are presented as mean±s.e.m. Data normality was assessed with Shapiro-Wilk 
or D'Agostino-Pearson omnibus tests. Comparisons of normally distributed data were made 
using 2-tailed Student’s t-tests. Equality of variance was assessed with an F test, and 
heteroscedastic t-tests were used if needed. Data that were not normally distributed were 
analysed with Mann-Whitney tests. P values were corrected for multiple comparisons using a 
procedure equivalent to the Holm-Bonferroni method (for N comparisons, the most significant 
p value is multiplied by N, the 2nd most significant by N-1, the 3rd most significant by N-2, 
etc.; corrected p values are significant if they are less than 0.05). Assessment of whether the 
slope of linear regressions differed significantly from zero was obtained using the t-statistic for 
the slope. P values comparing vessel diameters in the absence and presence of drugs were 
calculated for the last data point in each graph shown, or for an exposure time of 45-60 mins 
if no graph is shown. An estimate of the sample size needed for a typical experiment is as 
follows: For a control response of 100%, a response standard deviation of 10%, a response 
in a drug of 70% (30% inhibition), a power of 80% and p<0.05, less than 6 vessels are needed 
in each of the control and drug groups (www.biomath.info/power/ttest.htm). The exact 





Calculation of effect of vessel constriction on flow 
 We assume that pericytes are regularly spaced on capillaries at an interval of 2L. For 
flow governed by Poiseuille’s law, the resistance of a segment of capillary of length L (from a 
pericyte soma to midway between two pericytes) and radius r1 is given by  
k.L/r14  
where k is a constant. If A-induced pericyte contraction reduces the capillary diameter from 
a value of r1 at the midpoint between pericytes to r2 near the pericyte soma (see Fig. 4A, B, 
D), then if this reduction is linear with distance the resistance of the capillary segment from 
the soma to the midpoint is given by 
 k.L.(r12 + r1.r2 + r22)/(3.r13.r23) 
so the factor by which the resistance is altered (compared to that with a uniform diameter r1) 
is  
 [1 + (r1/r2) + (r1/r2)2].(r1/r2)/3       (1) 
Thus, with A deposition, the 30% pericyte constriction reported at pericyte somata in Fig. 4D 
will increase the resistance by a factor of 2.1, compared to a situation with the capillary having 
a uniform diameter equal to that measured far from the pericyte somata (~3.9 m in Fig. 4D), 
while the 27% increase in diameter at the soma in subjects without A deposition will decrease 
the resistance to 0.63 of the value with a uniform capillary. Taking the ratio of these changes 
leads to the conclusion that the capillary constriction occurring with A deposition will increase 
the capillary resistance by a factor of 3.4 (compared to the condition with no A deposition). 
Since the capillaries provide 57% of the total vascular resistance in the brain parenchyma 
(16), and the diameter of arterioles and venules is not changed (Fig. 5H), it follows that, if the 
pressure is fixed at the pial end of penetrating arterioles and venules, then cerebral blood flow 
will be decreased by 58% (calculated as (43%+57%)/(43%+3.4x57%)). In reality the flow 
reduction could be greater than this because Poiseuille’s law does not apply for small capillary 
diameters for which the effective blood viscosity increases as the diameter decreases below 
10 m (50). Importantly, the data in Fig. 4 were averaged over all visible pericytes in the 
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images, and so already take account of the fact that the contractility of capillary pericytes 
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Figure S1. Morphological identification of pericytes. 
Figure S2. Circumferential processes of pericytes are mainly near the soma. 
Figure S3. Constriction of capillaries by pericytes occurs predominantly at somata. 
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Figure 1. Oligomeric A acts on pericytes to constrict capillaries in human brain slices.  
(A) Isolectin B4 - labeled capillary in a human cortical slice, with two pericyte somata (arrow 
heads) outlined by their basement membrane. (B) Pericyte labeled with antibody to PDGFR. 
(C-D) Arteriole (C) and pericyte (D) labeled with isolectin B4 and antibody to  smooth muscle 
actin (-SMA, localised in processes originating from the pericyte soma). (E) Images of a 
capillary (red lines indicate diameter) and pericyte soma (arrowheads) in a live human brain 
slice before drug application (before), in the presence of 2 M superfused noradrenaline 
(+NA), with 2 M NA and 500 M glutamate superfused (+NA +Glu), and after stopping drug 
superfusion (washout). Graph shows time course of capillary diameter at red line throughout 
the experiment. (F) Mean (±s.e.m) glutamate-evoked dilation and noradrenaline-evoked 
constriction in experiments as in (E) (number of pericytes on bars; change in diameter was 
quantified relative to that before application of each drug; relative to the pre-noradrenaline 
diameter the glutamate-evoked dilation was 26.8±7.7%). (G) Silver staining of an SDS-PAGE 
gel for Aβ solutions prepared as in the Materials and Methods. (H) Images of a human capillary 
before and after superfusion of 72 nM A, showing a region (red line) being constricted by 
a pericyte (arrowheads). Graph shows mean (±s.e.m) diameter change at 4 pericyte locations 
from 4 slices treated with A and 3 pericyte locations from 3 slices superfused with aCSF 




Figure 2. A acts via reactive oxygen species and endothelin type A receptors. 
(A-B) Bright field images (A) and two-photon evoked IB4 fluorescence (B) of capillaries in rat 
cortical slices in aCSF and after applying 72 nM A1-42, showing constriction near pericytes 
(arrowheads, cf. Figs. S2, S3). (C) Mean (±s.e.m) time course of capillary diameter during 
superfusion with aCSF (n=51 vessels), scrambled A1-42 (109 nM, n=32), A1-42 (72 nM, n=20) 
or A1-40 (100 nM, n=6). (D) Constriction evoked after 1 hour by different concentrations of A1-
42 (n=51, 11, 10, 19 and 20 for 0, 2.9, 14, 57 and 72 nM respectively). Curve is a Michaelis-
Menten relation with a Km of 4.7 nM and a maximum of 16.1%. (E-J) Time course of diameter 
when applying the following agents (experiments on each figure panel were interleaved; 
blockers were present for 5-15 mins before A). (E) 57 nM A1-42 alone (n=19), or in the 
presence of superoxide dismutase 1 (SOD1, 150 units/ml, n=19) or the ETA blocker BQ-123 
(1 M, n=14). (F) 72 nM A1-42 alone (n=7), or in the presence of the NOS blocker L-NNA (100 
M, n=6), the NADPH oxidase blocker DPI (10 M, n=5), or the NOX4 blocker GKT137831 
(0.45 M, n=7). (G) Constriction produced at 60 mins for (C)-(F). (H) Effect of aCSF (n=10), 
ET alone (10 nM, n=10), or ET in the presence of the ETA blocker BQ-123 (1 M, n=10) or the 
ETB blocker BQ-788 (1 M, n=12). (I) aCSF or ET (5 nM) in the absence (n=12) or presence 
of SOD1 (150 units/ml, n=8). (J) aCSF or the ROS generator H2O2 (1 mM, n=9, which evokes 
constriction: p=1.1x10-5 at 20 mins) or H2O2 with the ETA blocker BQ-123 (1 M, n=11, 
constriction is reduced, p=0.009). (K) Two-photon image of mouse cortical pericyte expressing 
GCaMP5G (green), before and while applying ET (10 nM), which raises [Ca2+]i (increase in 
green intensity) in pericyte soma (arrowhead, dashed line shows ROI analysed) and 
processes, and constricts the capillary (see white line on image of the tdTomato reporter of 
GCaMP5G expression, red). (L) Mean [Ca2+]i time course in 8 pericyte somata in response to 
ET (significantly elevated, p=0.0014) and in 7 somata in aCSF (no significant change, p=0.74). 
(M) Incubating rat brain slices (number on bars) with A1-42 oligomers (1.4 M) or ET (100 nM) 




Figure 3. A evokes ROS generation in pericytes. 
(A) Fluorescence images of dihydroethidium (DHE) loaded rat cortical slices incubated in 
control aCSF or aCSF containing A1-42 (72 nM) or A1-42 + SOD1 (150 units/ml) for 40 min, 
showing that A increases ROS level, and this is inhibited by SOD1. (B) Fluorescence 
(normalised to value in aCSF, mean±s.e.m.) of slices incubated in aCSF (n=6), A1-42 (n=7) 
or A1-42 + SOD1 (n=6). (C) Left: Image of a cortical slice showing that the brightest DHE-
labeled cells are located on IB4-labeled blood vessels (arrowhead). Right: Immunolabeling 
shows that these cells colocalise with NG2, but not Iba1, implying that they are pericytes rather 
than microglia or perivascular macrophages. (D) Soma DHE fluorescence (arbitrary units 
(a.u.), mean±s.e.m.) from the population of pericytes, or of Iba1-labeled cells, after 40 mins in 
the absence or in the presence of A1-42. Numbers on bars are slices (fluorescence was 




Figure 4. Pericyte-mediated capillary constriction occurs in humans with A deposits. 
(A-B) Specimen images of human cortical biopsies, labeled for PDGFR (brown in top panels) 
to show pericytes (arrows), from patients lacking (A) or exhibiting (B) A deposits (brown in 
bottom panels, haematoxylin counterstain blue). Red lines indicate capillary diameter. (C) 
Mean (±s.e.m) diameter of capillaries in patients lacking (3921 diameters measured) or 
exhibiting (5121 diameters measured) A deposits (number of images analysed shown on 
bars). (D) Dependence of capillary diameter on distance from a visible pericyte soma (in 5 m 
bins, from 0-5, 5-10, 10-15 and 15-20 m, plotted at the mean distance for each bin) for 
patients lacking or exhibiting A deposits (moderate and severe A deposition pooled 
together). P values assess whether slope of regression line is significantly different from zero. 
(E) Examples of A labeling assessed by the neuropathologist as absent, moderate or severe. 
(F) Slope of regression lines as in (D) plotted as a function of neuropathologist-rated 
parenchymal A load for each biopsy (n=6 biopsies for none, n=3 for moderate, n=4 for 
severe). P value compares slope of line with zero. (G) Slope of regression lines as in (D) 
plotted as a function of severity of A deposition measured optically for each biopsy, with 
subjects grouped by colour (defined in (F)) as classified by neuropathologist. (H) Dependence 
of extrapolated diameter at soma (as in (D)) on severity of A deposition measured optically 
for each biopsy, with subject points coloured as classified by neuropathologist (defined in (F)). 




Figure 5. Capillaries, but not arterioles or venules, are constricted in AD mice. 
(A) Specimen images (taken through the dura) of blood vessels in the somatosensory 
neocortex of WT and homozygous AD (APPNL-G-F) NG2-DsRed mice, with FITC-albumin 
(green) in the blood (pericytes are labeled red). (B) Examples of single neocortical capillaries 
and pericytes, showing a larger diameter at the pericyte soma in a WT mouse and constriction 
of a capillary at the pericyte soma in an AD mouse. (C) Images of neocortex labeled for nuclei 
(DAPI, blue) and for amyloid plaques (green, 82E1 antibody). (D) Mean (±s.e.m) capillary 
diameter in neocortical layers I-IV in 3 WT mice (2131 diameters measured; measurements 
on same capillary were averaged) and 4 AD mice (1403 diameters measured). Numbers of 
capillaries are shown on bars. (E) Mean neocortical capillary diameter at pericyte somata in 3 
WT and 4 AD mice (number of pericytes on bars). (F) Plot of neocortical capillary diameter as 
a function of distance from pericyte somata shows a smaller diameter at the soma in AD mice 
and a larger diameter in WT mice (cf. Fig. 4D; each WT mouse studied showed a negative 
slope for this relationship, and each AD mouse showed a positive slope). (G) Plots as in (F) 
but for cerebellum, which lacks amyloid plaques, show no constriction near the pericyte 
somata in the AD mice (regression line is a fit to all data from 3 WT and 3 APP mice). (H) 
Mean diameter of neocortical penetrating arterioles and venules in WT and AD mice. Numbers 
of vessels are shown on bars. Diameters were assessed at depths that did not differ 
significantly: 158.4±6.7 m and 131.9±5.0 m (p=0.23 by Mann-Whitney test) for neocortical 
capillaries, 142±26 m and 137±21 m (p=0.88) for arterioles, and 85±15 m and 89±9 m 




Figure 6. A effects on capillaries may amplify the onset of AD, and are reversible. 
(A) Applying GKT137831 (0.45 M) to block NOX4 and BQ-123 (1 nM) to block ETARs, or C-
type natriuretic peptide (CNP, 100 nM, see Fig. S8), significantly reduced the constriction 
evoked by A (72 nM, p=0.027 and 0.029 respectively, corrected for multiple comparisons, 
data are presented as mean±s.e.m.). (B) Summary of our results and their implications. Our 
data reveal the pathway within the yellow dashed box. Amyloid  oligomers activate NADPH 
oxidase 4 in pericytes to generate reactive oxidative species (ROS). These in turn release, or 
potentiate the constricting effects of, endothelin-1 which acts via ETA receptors on pericytes 
on capillaries - the locus (16) of the largest component of vascular resistance within the brain 
parenchyma. Capillary constriction decreases cerebral blood flow and hence the supply of 
oxygen and glucose to the brain. Green arrows on the left show that this increases the 
production of A, in part by upregulating (13, 14) expression of -amyloid converting enzyme 
(-secretase 1, BACE1), thus forming an amplifying positive feedback loop. Blue arrows on 
the right show that a rise in A concentration, either directly, or via downstream tau production, 
or via the decrease in oxygen and glucose supply, leads to the loss of synapses and neurons. 
Potential sites for therapeutic intervention are highlighted at the stages of ROS production by 
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Fig. S1. Morphological identification of pericytes. 
(A) Bright field image showing a morphologically-identified candidate pericyte on a rat 
capillary, with the soma exhibiting the classical bump-on-a-log appearance. Pericytes 
were identified by the experimenter using images like this, without inspecting the IB4 
fluorescence. (B) Same field with IB4-Alexa-568 fluorescence excited, showing that the 
soma is surrounded by IB4-labeled basement membrane, and thus is confirmed to be a 
pericyte. In 26 out of 27 trials (96.3%), IB4 fluorescence confirmed the morphologically 






Fig. S2. Circumferential processes of pericytes are mainly near the soma. 
(A) Confocal image (maximum intensity projection) of a mouse capillary pericyte 
transgenically labeled with dsRed under the NG2 promoter, showing circumferential 
processes at different distances from the soma. (B) Distribution of the percentage of 
circumferential processes (per 2.5 m bin) as a function of distance along the capillary 
from the centre of the somata of 34 pericytes. To be defined as “circumferential”, and 
thus potentially able to reduce capillary diameter when contracted, a process had to run at 
>35o to the axis of the capillary. Defined thus, 77% of circumferential processes were 






Fig. S3. Constriction of capillaries by pericytes occurs predominantly at somata. (A) 
Time course of capillary constriction at different distances from 5 rat pericytes on 
application of the thromboxane A2 analogue U46619 (200 nM). A greater constriction is 
produced near the somata. (B) Mean diameter as a function of distance from pericyte 
somata before U46619 was applied (control) and after 20 mins application (+U46619). 
Note larger mean diameter near the somata in the absence of vasoconstrictor, as is found 
in non-AD biopsy tissue from human subjects (Fig. 4D) and in vivo in non-AD mice 
(Fig. 5F). (C) Percentage constriction (from panel B) in U46619 as a function of distance 
from the somata shows that the constriction reflects the distribution of circumferential 













Fig. S4. A depletes reduced glutathione (GSH) in pericytes and microglia. 
(A) Representative images of microglia (red arrows) and pericytes (white arrows) labeled 
for GSH (right panels) in rat neocortical slices. Top panels: control conditions, when 
microglia show a higher level of GSH than pericytes (note that the pericyte nucleus does 
not label for GSH). Bottom panels: in the presence of 72 nM A, which lowers the GSH 
level in both pericytes and microglia. Yellow dashed lines indicate measurement ROIs. 
(B) Quantification of GSH level for the population of  pericytes and microglia averaged 
across 3 images from each slice. Numbers on bars are of slices. Quantification per 















Fig. S5. Amyloid plaques in different regions of AD mouse brain. 
(A, B) Wild-type (WT, A) and AD (APP, B) brains labeled with DAPI (blue) and for 
amyloid plaques with 82E1 antibody (green). Green areas at the edge of tissue regions are 
artefacts (resulting from the automated scanner for the image acquisition changing focus), 
and were excluded from the quantitative analysis (C) Quantification of fraction of area 













Fig. S6. Endothelin-1 has different effects on capillaries and arterioles. 
(A) Images of a representative arteriole in a rat cortical brain slice showing its response 
to ET (10 nM), with an initial dilation, followed by a constriction. (B) Mean time course 
of biphasic response to ET (black dots, n=10 arterioles), which does not occur with aCSF 
(red, n=8). These diameter changes are abolished by the ETA blocker BQ-123 (blue, 1 
nM, n=11). Blocking ETB receptors with BQ-788 (green, 1M, n=6) abolishes the 
dilation and greatly speeds the constriction evoked by ET. (C) The constriction evoked 
by ET in arterioles (black, n=10) is much slower than that evoked in capillaries (green, 
n=10). Blocking NO synthase with L-NNA (1 mM) greatly speeds the constriction 
evoked by ET in arterioles (blue, n=12) but has little effect on the speed of the 




labeled). These experiments suggest a reason for the lack of a constriction of arterioles by 
endogenous A in the AD mice, as follows. Endothelin-1 evokes an initial dilation of 
arterioles followed by a constriction that was much slower than that seen for capillaries 
(panels A-C). Blocking ETB receptors or NOS converts this biphasic response into a 
constriction with a time course similar to that seen in capillaries (panels B-C). This is 
consistent with arteriolar smooth muscle contracting (like pericytes) when endothelin-1 
activates ETA receptors on the contractile cells, but with the activation of ETB receptors 
linked to NOS (probably in endothelial cells or interneurons) evoking an opposing 
arteriole dilation. Presumably, at the levels of endogenous A and endothelin-1 reached 
in AD, the dilation and constriction approximately cancel out (as no diameter change was 
seen in arterioles in AD mice), whereas with application of exogenous A in previous 






Fig. S7. Oxygen levels are lower in the cortex of AD mice. 
(A-B) Representative images of sections of cortex from 4 month old WT (A) and AD 
(APP, B) mice, labeled with pimonidazole (green) and NG2-DsRed (red), showing more 
labeling in the AD mouse, where the labeling intensity was higher on the venous side of 
the vasculature (as seen previously (51)) and there was sparse bright labeling of hypoxic 
neurons (yellow arrows, these might be interneurons that are firing at a high rate (52), 
and thus may be more metabolically challenged, therefore showing larger hypoxia in the 
AD mice which have constricted capillaries). (C) Expanded view of a hypoxic neuron. 
(D) Quantification of number of hypoxic neurons (per 400 m x 400 m, x 10 m deep 
stack) in AD (APP) and wild-type (WT) mice. In WT mice 21 stacks from 3 mice were 







Fig. S8. Pathways regulating pericyte contraction. 
Schematic diagram of a pericyte with a contractile process around a capillary. A 
generates ROS (via NOX4) which evoke release of endothelin-1 (ET), which can activate 
contraction by binding to ETA receptors. These generate IP3 to release Ca
2+ from internal 
stores, which evokes contraction by activating myosin light chain kinase (MLCK). This 
pathway can be inhibited by blocking NOX4 with GKT137831 (GKT) and blocking ETA 
receptors with BQ-123. Alternatively, C-type natriuretic peptide (CNP) can block the ET-
evoked contraction by acting on guanylate cyclase receptors that generate cGMP. This 
inhibits Ca2+ release from stores by activating protein kinase G to phosphorylate the IP3R 
interacting protein IRAG. cGMP also inhibits cAMP phosphodiesterase 3A (PDE3A) 
leading to a rise of [cAMP] which activates protein kinase A (PKA) which in turn 
activates myosin light chain phosphatase (MLCP) to inhibit contraction. 
 
